15b ichiro aramori, astellas pharma, breakout 2

Symposium on UK UK-Japan Japan university university-industry industry partnerships Building International University-Business links

AK project

(Astellas -Kyoto Univ. Project)

Ichiro Aramori, PhD, Astellas Pharma Inc project j

Astellas AK Project Leader Professor , Kyoto Univ., Grad.Sch. Med. at the British Embassy Tokyo on 10 January, 2012

1

Industry--Academia Industry Academia--Government collaborations Drug Target Discovery y

Optimization Seed/lead リード探 (Screening) 索最適 索 compounds p (Tox,Metabolism) 化

Non-clinical studies

Clinical development

E plorator research for drug Exploratory dr g target disco discovery er Joint research projects with universities and research institutes in Japan and abroad

Enhancing g the compound p discovery y ability y ((drug g designing) g g) Structural analysis of proteins with the High Energy Accelerator Research Organization

Increases in the speed p and quality q y of toxicity y assessment Toxicogenomics with the NIBIO and the National Institute of Health Sciences

Promotion of translational sciences Bio-imaging using PET in cooperation with the Medical and Pharmacological Research Center Foundation, Translational research with Tsukuba Univ. Hospital

Fusion of drug discovery and medical science and R&D of drugs

Development of immunoregulatory drugs with Kyoto Univ. (AK-PJ)

2

Cooperation between Industry and Academia g Discovery y Network for Drug â—?Researchers from companies: no direct access to patients and unable to study diseases â—?University researchers engaged in basic study or clinical medicine have no drug discovery technology â—?Cooperation between industry and academia: to develop drugs that meet unmet medical needs using information f on diseases obtained ffrom patients.

Delivery D li off drugs d to t patients ti t developed using information obtained from them

Patients

Academia: studies on diseases and identification of targets o drug d ug discovery d sco e y for

Companies: d drug discovery

3

The Center for Innovation in Immunoregulative Technology gy and Therapeutics p (AK ( project) p j )

Best Drugs on Best Science!

Kyoto University Advanced immunology research

Astellas Discovery of global medicine

Drugs for immunoregulation Cure of intractable diseases and Novel immunoregulation technologies for transplantation  Special coordination funds for promoting science and technology  Long-term, large-scale collaboration system (10 years, 2007 - )  Identification and validation of new drug targets/biomarkers (Kyoto Univ.)  Drug discovery and development (Astellas)  Innovation of drug discovery system  Establishment of an intellectual property management system necessary for the industry-academia industry academia collaboration  Encourage the talents comprehensive for medical research, drug discovery and intellectual properties

Organization of Research at AK Project Identification of Biomarkers

Kyoto y Univ. Astellas Fusion Lab.

Clinical Dept.

Groups ďźˆClinical Res. Grant 3 Core Professors and their team Narumiya Lab Minato Lab Sakaguchi Lab

Lab. Supervisor Lab. Sub-supervisor Advice on research and development

15 Young Investigator Groups

Intellectual Property Office Coordinates p publication and patent application Translational Research Center

3 Astellas Groups

Technical support Groups

Astellas Drug Discovery

Identification and Validation of New Drug Targets Prediction of clinical usefulness of Targets/Compounds 5

Road map and Achievements 2007

2010

Set up Fusion Lab.

2012

2014

2017

Started Clinical Res. Grants.

Expand Fusion Lab. Lab

Identification of targets ( > 25) Establishment of platform technologies for early prediction of clinical usefulness of compounds p D Drug di discovery research h Candidates (>3)

Targets identified in Kyoto University ⇒ 15 Patent applications 19 Papers >100 Drug discovery programs in Astellas ⇒ 7 High throughput screening Antibodies Evaluation of the compounds/antibodies

6